# A Clinical Study of SHR-1314 Injection in the Treatment of Moderate to Severe Plaque Psoriasis in Adults

> **NCT04121143** · PHASE2 · SUSPENDED · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 120 (estimated)

## Conditions studied

- Plaque Psoriasis

## Interventions

- **BIOLOGICAL:** IL-17A Antagonist
- **BIOLOGICAL:** Placebos

## Key facts

- **NCT ID:** NCT04121143
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2019-11-09
- **Primary completion:** 2020-06-30
- **Final completion:** 2020-12-30
- **Target enrollment:** 120 (ESTIMATED)
- **Why stopped:** sponsor's decision
- **Last updated:** 2020-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04121143

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04121143, "A Clinical Study of SHR-1314 Injection in the Treatment of Moderate to Severe Plaque Psoriasis in Adults". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04121143. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*